• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Eton Pharmaceuticals Inc.

    10/30/25 3:18:47 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ETON alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Eton Pharmaceuticals Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    29772L108

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    29772L108


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    160,477.00
    7Sole Dispositive Power

    1,174,647.00
    8Shared Dispositive Power

    169,468.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,344,115.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.01 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Eton Pharmaceuticals Inc
    (b)Address of issuer's principal executive offices:

    21925 West Field Parkway, Suite 235, Deer Park, IL, 60010
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    29772L108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1344115
    (b)Percent of class:

    5.01  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    160477

     (iii) Sole power to dispose or to direct the disposition of:

    1174647

     (iv) Shared power to dispose or to direct the disposition of:

    169468

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:10/30/2025
    Get the next $ETON alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ETON

    DatePrice TargetRatingAnalyst
    1/23/2025$17.00 → $33.00Buy
    H.C. Wainwright
    1/10/2025$21.00Buy
    B. Riley Securities
    1/6/2025$15.00 → $17.00Buy
    H.C. Wainwright
    9/4/2024$9.00Buy
    H.C. Wainwright
    5/6/2024$8.00Buy
    Craig Hallum
    10/14/2021$10.00Buy
    B. Riley Securities
    More analyst ratings

    $ETON
    SEC Filings

    View All

    SEC Form 10-Q filed by Eton Pharmaceuticals Inc.

    10-Q - Eton Pharmaceuticals, Inc. (0001710340) (Filer)

    11/6/25 4:28:53 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)

    11/6/25 4:25:32 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Eton Pharmaceuticals Inc.

    SCHEDULE 13G - Eton Pharmaceuticals, Inc. (0001710340) (Subject)

    10/30/25 3:18:47 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results

    Q3 2025 product sales of $22.5 million, representing 129% growth over Q3 2024 and 19th straight quarter of sequential product sales growthQ3 2025 basic and fully diluted GAAP EPS of $(0.07), non-GAAP fully diluted EPS of $0.04, and Adjusted EBITDA of $2.9 millionET-600 NDA accepted for review, assigned PDUFA date of February 25, 2026GALZIN® launch ahead of plan; exceeded previous year-end target of 200 active patientsHeld positive FDA meeting clarifying pathway to KHINDIVI™ label expansionSubmitted proposed clinical study to support INCRELEX® label expansionGenerated $12.0 million of cash from operations in the quarterManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., No

    11/6/25 4:05:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

    DEER PARK, Ill., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Participant Call Link:Click HereWebcast:Click Here   In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@eto

    10/23/25 4:30:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

    DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host 1x1 meetings at the 2025 Wells Fargo Healthcare Conference being held September 3-5, 2025 in Boston, MA. To schedule a 1x1 meeting with the Company, please contact your Wells Fargo institutional sales representative. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has

    8/20/25 6:50:00 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Opaleye Management Inc. bought $125,484 worth of shares (7,930 units at $15.82) (SEC Form 4)

    4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

    6/12/25 4:32:51 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Opaleye Management Inc. bought $79,814 worth of shares (10,000 units at $7.98) (SEC Form 4)

    4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

    10/25/24 4:05:24 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Opaleye Management Inc. bought $434,137 worth of shares (62,070 units at $6.99) (SEC Form 4)

    4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

    10/8/24 6:34:32 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright reiterated coverage on Eton Pharmaceuticals with a new price target

    H.C. Wainwright reiterated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $33.00 from $17.00 previously

    1/23/25 9:02:14 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Eton Pharmaceuticals with a new price target

    B. Riley Securities initiated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $21.00

    1/10/25 7:49:32 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright reiterated coverage on Eton Pharmaceuticals with a new price target

    H.C. Wainwright reiterated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $17.00 from $15.00 previously

    1/6/25 8:01:16 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Gruber James R. sold $673,714 worth of shares (41,713 units at $16.15), decreasing direct ownership by 16% to 204,753 units (SEC Form 4)

    4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

    8/20/25 5:14:03 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Business Officer Krempa David sold $504,318 worth of shares (34,000 units at $14.83), decreasing direct ownership by 5% to 612,646 units (SEC Form 4)

    4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

    6/16/25 4:56:08 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Opaleye Management Inc. bought $125,484 worth of shares (7,930 units at $15.82) (SEC Form 4)

    4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

    6/12/25 4:32:51 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    Financials

    Live finance-specific insights

    View All

    Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results

    Q3 2025 product sales of $22.5 million, representing 129% growth over Q3 2024 and 19th straight quarter of sequential product sales growthQ3 2025 basic and fully diluted GAAP EPS of $(0.07), non-GAAP fully diluted EPS of $0.04, and Adjusted EBITDA of $2.9 millionET-600 NDA accepted for review, assigned PDUFA date of February 25, 2026GALZIN® launch ahead of plan; exceeded previous year-end target of 200 active patientsHeld positive FDA meeting clarifying pathway to KHINDIVI™ label expansionSubmitted proposed clinical study to support INCRELEX® label expansionGenerated $12.0 million of cash from operations in the quarterManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., No

    11/6/25 4:05:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

    DEER PARK, Ill., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Participant Call Link:Click HereWebcast:Click Here   In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@eto

    10/23/25 4:30:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results

    Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18th straight quarter of sequential product sales growthQ2 2025 basic and fully diluted GAAP EPS of $(0.10), non-GAAP fully diluted EPS of $0.03, and Adjusted EBITDA of $3.1 millionLaunched KHINDIVI™ (hydrocortisone) Oral SolutionReached 100 active INCRELEX® patients, ahead of previous guidance of year endCompany projects reaching an annual revenue run rate of $80 million in Q3, one quarter ahead of previous guidanceManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative phar

    8/7/25 4:05:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    Leadership Updates

    Live Leadership Updates

    View All

    Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

    Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical companies and across the broader health and wellness sector, including significant experience in the pediatric endocrinology specialty. DEER PARK, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Ipek Erdogan-Trinkaus as Chief Commercial Officer (CCO). Ms. Erdogan-Trinkaus brings to the Company broad commercial experience in the pharmaceutical

    12/3/24 6:50:00 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer

    DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of James Gruber as Chief Financial Officer, effective immediately. He succeeds Wilson Troutman, who is retiring. Mr. Troutman will remain with the company through the end of May to ensure a smooth transition. "We are pleased to welcome James to the Eton team. He brings a wealth of experience managing the finance and accounting activities for some of the most successful companies in the industry. We look forward to benefiting from his financial expertise as we

    4/11/22 4:01:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director

    LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a non-executive independent director of the board of directors of the Company (the "Board"). He will hold office as an independent director until the next annual meeting of shareholders, or until his successor has been elected or appointed. Mr. Maier has also been appointed as a member of the Audit Committee and Corporate Governance and Nominating Committee and Chair of the Compensation Committee. Mr. Maier joins Small Pharma with over 30 years' ex

    11/18/21 2:04:01 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Eton Pharmaceuticals Inc.

    SC 13G - Eton Pharmaceuticals, Inc. (0001710340) (Subject)

    12/9/24 4:04:43 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Eton Pharmaceuticals Inc.

    SC 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)

    9/12/24 4:05:13 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Eton Pharmaceuticals Inc. (Amendment)

    SC 13D/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)

    4/30/24 7:00:15 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care